About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Genetic Test for Plavix Use may Not be Necessary

by Kathy Jones on December 30, 2011 at 5:10 PM
Font : A-A+

 Genetic Test for Plavix Use may Not be Necessary

The usefulness of a genetic test for patients taking the anti-coagulant drug Plavix has been questioned in a new study, thus calling into question last year's FDA warning about the blood thinner.

The study, a new review of 32 previous clinical studies published in the Journal of the American Medical Association, said the genetic test may not help identify those patients more at risk of a heart attack or other cardiac event.

Advertisement

Plavix, one of the world's top selling drugs, is marketed by US-based Bristol-Myers Squibb and France's Sanofi. It reduces the risk of heart attack and stroke by keeping blood platelets from sticking together to cause clots.

In 2010, the US Food and Drug Administraion ordered the manufacturers to add a boxed warning to Plavix packets saying the drug may be less effective in preventing heart attacks in people who cannot metabolize it properly.
Advertisement

The FDA said an estimated two to 14 percent of the US population are poor metabolizers who have a certain variant of the gene that makes the CYP2C19 liver enzyme, which converts Plavix to its active form.

The FDA had recommended that doctors prescribe higher doses of Plavix, or clopidogrel, to those patients who had the genetic test and were found not to produce enough of the enzyme.

But researchers led by Michael Holmes at University College London concluded after their new review of studies involving 42,000 patients that those with the gene variant did not have more cardiac events than other patients.

"Despite associations between CYP2C19 genotype, clopidogrel metabolism, and platelet aggregation, this systematic review and meta-analysis does not demonstrate a clinically important association of genotype with cardiovascular outcomes," researchers led by Michael Holmes at University College London said.

The only notable possible exception was in patients with stent thrombosis, they wrote.

"The FDA's warnings on Plavix were premature and were not based on solid science," said Steven Nissen, a cardiologist at the Cleveland Clinic Foundation, in an editorial published in the Journal of the AMA.

Plavix sales totalled $5.4 billion in the first three quarters of 2011, as compared with $4.9 billion in the same period last year.

About 40 million people take the drug worldwide.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Genetics and Stem Cells Varicocele Top Ten Selling Drugs Christianson Syndrome 

Most Popular on Medindia

Diaphragmatic Hernia Post-Nasal Drip Blood - Sugar Chart Find a Doctor Sinopril (2mg) (Lacidipine) Vent Forte (Theophylline) Indian Medical Journals Turmeric Powder - Health Benefits, Uses & Side Effects Blood Pressure Calculator Selfie Addiction Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Genetic Test for Plavix Use may Not be Necessary Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests